GLUCOTRACK ANNOUNCES ORAL & POSTER PRESENTATIONS AT THE 2024 DIABETES TECHNOLOGY MEETING
Glucotrack, Inc. (Nasdaq: GCTK) announced that updated preclinical data for its continuous blood glucose monitor (CBGM) will be presented at the 24th Annual Diabetes Technology Meeting from October 15-17, 2024, in Burlingame, California. Mark Tapsak, PhD, Vice President of Sensor Technology, will deliver an oral presentation titled "The Technology Behind Continuous Blood Glucose Monitoring" on October 17.
The company will also present two posters: "In Vivo Evaluation of Novel Long-Term Intravascular Continuous Blood Glucose Monitor in a Chronic Ovine Model" and "Exploratory Study of Continuous Glucose Monitoring in the Epidural Space in Swine". These presentations aim to showcase the CBGM's ability to accurately measure glucose levels without the lag time associated with interstitial glucose and without an on-body wearable, potentially offering a less intrusive approach for people with diabetes.
Glucotrack, Inc. (Nasdaq: GCTK) ha annunciato che dati preclinici aggiornati per il suo monitoraggio continuo della glicemia (CBGM) saranno presentati al 24° Congresso Annuale sulla Tecnologia del Diabete che si terrà dal 15 al 17 ottobre 2024 a Burlingame, California. Mark Tapsak, PhD, Vice Presidente della Tecnologia dei Sensori, terrà una presentazione orale intitolata "La Tecnologia Dietro il Monitoraggio Continuo della Glicemia" il 17 ottobre.
La società presenterà anche due poster: "Valutazione In Vivo di un Nuovo Monitor di Glicemia Intravulare Continuo a Lungo Termine in un Modello Ovin Cronico" e "Studio Esplorativo sul Monitoraggio Continuo della Glicemia nello Spazio Epidurale nei Suini". Queste presentazioni mirano a dimostrare la capacità del CBGM di misurare con precisione i livelli di glucosio senza il tempo di latenza associato al glucosio interstiziale e senza un dispositivo indossabile, offrendo potenzialmente un approccio meno invasivo per le persone affette da diabete.
Glucotrack, Inc. (Nasdaq: GCTK) anunció que los datos preclínicos actualizados para su monitor de glucosa en sangre continuo (CBGM) se presentarán en la 24ª Reunión Anual de Tecnología en Diabetes que se llevará a cabo del 15 al 17 de octubre de 2024 en Burlingame, California. Mark Tapsak, PhD, Vicepresidente de Tecnología de Sensores, ofrecerá una presentación oral titulada "La Tecnología Detrás del Monitoreo Continuo de Glucosa en Sangre" el 17 de octubre.
La compañía también presentará dos carteles: "Evaluación In Vivo de un Nuevo Monitor de Glucosa en Sangre Intravascular Continuo a Largo Plazo en un Modelo Ovino Crónico" y "Estudio Exploratorio de Monitoreo Continuo de Glucosa en el Espacio Epidural en Cerdos". Estas presentaciones tienen como objetivo mostrar la capacidad del CBGM para medir con precisión los niveles de glucosa sin el tiempo de retraso asociado con la glucosa intersticial y sin un dispositivo portátil en el cuerpo, lo que potencialmente ofrece un enfoque menos invasivo para las personas con diabetes.
글루코트랙, 인크. (나스닥: GCTK)은 2024년 10월 15일부터 17일까지 캘리포니아 벌링게임에서 열리는 제24회 연례 당뇨병 기술 회의에서 지속적인 혈당 모니터(CBGM)의 업데이트된 전임상 데이터를 발표할 것이라고 발표했습니다. Mark Tapsak, PhD, 센서 기술 부사장은 10월 17일 "지속적인 혈당 모니터링의 기술"이라는 제목으로 구두 발표를 할 예정입니다.
회사는 또한 두 개의 포스터를 발표할 예정입니다: "만성 양모 모델에서의 신규 장기 혈관 내 지속적 혈당 모니터에 대한 In Vivo 평가"와 "돼지의 경막외 공간에서의 지속적 혈당 모니터링에 대한 탐색적 연구"입니다. 이러한 발표는 CBGM이 조직 혈당과 관련된 지연 시간 없이 정확하게 혈당 수치를 측정할 수 있는 능력을 보여주는 것을 목표로 하며, 몸에 착용할 필요가 없어 당뇨가 있는 사람들에게 더 적은 침습적인 접근 방식을 제공할 수 있습니다.
Glucotrack, Inc. (Nasdaq: GCTK) a annoncé que des données précliniques mises à jour pour son moniteur de glycémie continue (CBGM) seront présentées lors de la 24e Réunion Annuelle sur les Technologies du Diabète qui se déroulera du 15 au 17 octobre 2024 à Burlingame, Californie. Mark Tapsak, PhD, Vice-Président de la Technologie des Capteurs, fera une présentation orale intitulée "La Technologie derrière le Moniteur de Glycémie Continue" le 17 octobre.
L'entreprise présentera également deux affiches : "Évaluation In Vivo d'un Nouveau Moniteur de Glycémie Intravasculaire Continue à Long Terme dans un Modèle Ovin Chronique" et "Étude Exploratoire sur le Moniteur de Glycémie Continue dans l'Espace Épidural chez les Porcs". Ces présentations visent à montrer la capacité du CBGM à mesurer avec précision les niveaux de glucose sans le temps de latence associé au glucose interstitiel et sans dispositif portable, offrant potentiellement une approche moins invasive pour les personnes atteintes de diabète.
Glucotrack, Inc. (Nasdaq: GCTK) hat angekündigt, dass aktualisierte präklinische Daten zu ihrem kontinuierlichen Blutzucker-Monitor (CBGM) auf der 24. Jahrestagung der Diabetes-Technologie vom 15. bis 17. Oktober 2024 in Burlingame, Kalifornien, präsentiert werden. Mark Tapsak, PhD, Vizepräsident der Sensortechnologie, wird am 17. Oktober einen mündlichen Vortrag mit dem Titel "Die Technologie hinter der kontinuierlichen Blutzuckermessung" halten.
Das Unternehmen wird auch zwei Poster präsentieren: "In Vivo-Bewertung eines neuartigen langfristigen intravasalen kontinuierlichen Blutzucker-Monitors in einem chronischen Schafmodell" und "Explorative Studie zur kontinuierlichen Blutzuckermessung im Epiduralraum bei Schweinen". Diese Präsentationen zielen darauf ab, die Fähigkeit des CBGM zu demonstrieren, die Glukosewerte genau zu messen, ohne die Verzögerungszeit, die mit interstitieller Glukose verbunden ist, und ohne ein tragbares Gerät, was potenziell einen weniger invasiven Ansatz für Menschen mit Diabetes bietet.
- Glucotrack will present updated preclinical data for its CBGM at a major diabetes technology conference
- The company's CBGM technology claims to measure glucose levels without lag time and without an on-body wearable
- Glucotrack's presentation at the conference may increase visibility and credibility in the diabetes technology sector
- The data presented is still preclinical, indicating the product is not yet ready for market
- No specific performance metrics or comparative advantages over existing technologies are mentioned in the PR
Updated preclinical data for the continuous blood glucose monitor to be presented at major diabetes technology conference
Rutherford, NJ, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that updated preclinical data for its continuous blood glucose monitor (“CBGM”) will be presented at the 24th Annual Diabetes Technology Meeting, to be held from October 15-17, 2024, in Burlingame, California.
The Diabetes Technology Meeting is a highly regarded forum where the latest advancements in diabetes technology are presented and discussed. The meeting covers a wide range of topics, including new high-tech tools, automated insulin delivery systems, and innovations in continuous glucose monitoring.
Mark Tapsak, PhD, Vice President of Sensor Technology, will deliver the oral presentation, titled “The Technology Behind Continuous Blood Glucose Monitoring” on Thursday, October 17, 2024. “We are pleased to highlight updated preclinical data on Glucotrack’s CBGM," said Dr. Tapsak. "These data extend the results that have previously been presented and support the ability of the CBGM to accurately measure glucose levels without the lag time associated with interstitial glucose. The ability of our novel technology to provide real-time continuous glucose monitoring over an extended period and without an on-body wearable will enable a less intrusive approach to daily living for people with diabetes.”
Two posters will also be presented at the meeting. The posters will be made available on the Glucotrack website following the poster session at the conference. The poster sessions are Tuesday, October 15, 2024 from 4:30 – 6:30 PM and Wednesday, October 16, 2024 from 5:00 – 7:00 PM.
Poster #1 Title: In Vivo Evaluation of Novel Long-Term Intravascular Continuous Blood Glucose Monitor in a Chronic Ovine Model
Poster #2 Title: Exploratory Study of Continuous Glucose Monitoring in the Epidural Space in Swine
For more information about Glucotrack’s CBGM, visit glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
# # #
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
Glucotrack’s CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. For more information, please visit http://www.glucotrack.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC on March 28, 2024.
Contacts:
Investor Relations:
investors@glucotrack.com
Media:
GlucotrackPR@icrinc.com
FAQ
What will Glucotrack (GCTK) present at the 2024 Diabetes Technology Meeting?
Who will deliver the oral presentation for Glucotrack (GCTK) at the 2024 Diabetes Technology Meeting?
What are the titles of Glucotrack's (GCTK) poster presentations at the 2024 Diabetes Technology Meeting?
What are the claimed advantages of Glucotrack's (GCTK) continuous blood glucose monitor?
